Advanced Machine Learning Engineer, BenevolentAI

Salary not provided

AWS

Kubernetes

GCP

Python

Airflow

Tensorflow

Spark

PyTorch

Sagemaker

Senior level

London

More information about location

AI-drug discovery

Job no longer available

AI-drug discovery

201-500 employees

HealthcareB2BArtificial IntelligenceEnterpriseBiologyMachine LearningScience

Job no longer available

Salary not provided

AWS

Kubernetes

GCP

Python

Airflow

Tensorflow

Spark

PyTorch

Sagemaker

Senior level

London

More information about location

201-500 employees

HealthcareB2BArtificial IntelligenceEnterpriseBiologyMachine LearningScience

Company mission

BenevolentAI's mission is to unlock the power of AI to transform drug discovery and bring effective medicines to every patient. Their vision is to drive transformational change through scalable technology solutions that result in a consistent pipeline of successful trials and new medicines for patients.

Job

Company

Role

Who you are

An inherent interest in drug-discovery with a team player mindset
An MSc or PhD in computer science, machine learning, or a related discipline
Good Python coding skills
Experience working with PyTorch, Tensorflow, jax or other deep learning frameworks
Experience with AWS/GCP
Knowledge of machine learning and deep learning fundamentals
Experience with model training in GPUs and orchestration of data/modelling pipelines
Experience working with kubernetes, Spark, Weights and Biases, Sagemaker (or other model serving frameworks) and/or large scale biomedical datasets would be pluses

What the job involves

BenevolentAI is seeking to hire a talented Machine Learning Engineer to contribute to the development of our industry-leading AI models
The Senior Machine Learning Engineer is a key role which will contribute to model productionisation, data engineering, and accelerating model development
You will work closely with the Lead Machine Learning Engineering and be a member of a multidisciplinary team of AI Scientists, Software Engineers, Informaticians and Drug Discoverers
You will productionise models across Product and Tech that support a range of drug discovery and development phases including target identification and chemistry
You will speed up model development by simplifying, orchestrating, automating or distributing workflows
You will work in collaboration with users from different disciplines, providing them with regular updates and incorporating their feedback into your products
You will share knowledge and results of your work, promote best practice and onboard users
You will ensure that engineering is of the highest quality, that we track experiments and our models are reproducible
You will collaborate with AI scientists and contribute to new model development ideas
You will develop tools and workflows using Airflow, Kubernetes, Spark, PyTorch and more

Salary benchmarks

Our take

There is a lot of research being done in the pharmaceutical industry. BenevolentAI say there's a new research paper being published every 30 seconds. They argue this information is not being used in a smart way for the discovery and development of new drugs.

To tackle this problem, BenevolentAI uses artificial intelligence to analyse biomedical information, from clinical trials data to academic papers. They can then identify molecules that have failed in clinical trials and predict how these same compounds can instead be more efficient targeting other diseases.

They argue this approach can dramatically accelerate the discovery of new drugs. They've collaborated with large pharma companies like AstraZeneca and Johnson & Johnson subsidiary Janssen Pharmaceutica. A SPAC merger of 1.5 billion euros included AstraZeneca as an investor and will help BenevolentAI accelerate product development.

It's a big market, with Global Market Insights estimating the global healthcare AI market will exceed $10 billion by 2024. This gives them a big opportunity, but it won't be an easy problem to tackle.

Steph

Company Specialist at Welcome to the Jungle

Insights

Top investors

51% female employees

15% employee growth in 12 months

Glassdoor (4.1)

Company

Funding (last 2 of 3 rounds)

Sep 2019

$90m

LATE VC

Apr 2018

$115m

LATE VC

Total funding: $305m

Company benefits

Work from home opportunities

Company HQ

Fitzrovia, London, UK

Leadership

Joanna Shields

(CEO, not founder)

Long career in technology, having previously worked at Google, Facebook and Bebo. Appointed to the House of Lords in 2014 and works as a Digital Economy Adviser to the UK Government.

Michael Brennan

(Co-founder & Non-Executive Director)

Previously Head of Corporate Development at BenevolentAI. Before cofounding the company, they were Head of Corporate Development at Proximagen Group and Chief Executive of Novum Securities.

Ivan Griffin

(Co-founder & COO)

Worked as a Venture Capitalist for over a decade. Also helped launch Genomics England Ltd, a Company created to deliver the 100,000 Genomes Project as launched by the Prime Minister in 2013. Holds a D.Phil. in Cognitive Neuroscience from the University of Oxford where they also completed a year’s post-doctoral research.

Share this job